SPORE in Genitourinary Cancer

描述（由申请人提供）：德克萨斯大学MD安德森癌症中心生殖泌尿系统癌项目的总体目标是促进该疾病的预防、检测和治疗方面的创新转化研究，从而消除作为主要健康问题的膀胱癌（BC）。我们投资了几个主要的转化研究主题，包括：开发无创或微创标记物，用于高风险人群的早期BC检测，或用于监测和早期发现BC患者的复发，确定导致BC风险增加或降低的遗传因素，阐明介导尿路上皮肿瘤早期阶段的分子事件（遗传和表观遗传），确定bc中存在的激活突变和基因扩增是否驱动癌症进展并作为潜在的治疗靶点，鉴定可用于区分非肌肉侵入性和更晚期疾病的“有利”和“不利”生物学的分子和生物学标记，从而指导我们进行最佳治疗（“个性化医疗”）；开发非肌肉浸润性BC的新治疗方法，替代卡介苗（BCG）和/或有效治疗BCG难治性疾病，以及鉴定治疗转移性BC的新药物。为了实现这些目标，我们的SPORE汇集了临床医生和基础科学家，包括泌尿科医生、医学肿瘤学家、病理学家、分子流行病学家、分子和细胞生物学家、生物统计学家以及新技术和信息学开发专家。SPORE包括5个相互关联的项目，涉及：1)BC的早期检测；2)BC的风险评估；3)成纤维细胞生长因子受体的生物学和治疗靶向；3)Ral GTPases的治疗靶向；5)腺病毒介导的难治性肿瘤基因治疗的发展。这些项目得到3个核心的支持：(A)行政；(B)。生物统计学和生物信息学；(C)病理与数据管理。所有的科学项目本质上都是转化的；关注人类BC；包括临床和基础研究人员以及生物统计学家；与其他项目进行互动；利用核心资源。创新的发展和职业发展项目带来了新的研究人员，并刺激了每个主要项目中所代表的孢子。本提案的目的和目标的实现将导致BC的发病率、发病率和死亡率的大幅下降。

DESCRIPTION (provided by applicant): The overall goal of this University of Texas MD Anderson Cancer Center SPORE in Genitourinary Cancer is to facilitate innovative translational research in the prevention, detection, and treatment of this disease leading to the elimination of bladder cancer (BC) as a major health problem. We have invested in several major translational research themes which include: the development of non- or minimally-invasive markers for early detection of BC in high-risk individuals or for surveillance and the early detection of recurrence in those with the disease, the identification of inherited factors that contribute to increased or decreased risk of developing BC, the elucidation of the molecular events (genetic and epigenetic) that mediate the earliest stages of urothelial neoplasia, the determination of whether activating mutations and gene amplifications present in BCs drive cancer progression and serve as potential therapeutic targets, the identification of molecular and biological markers that can be used to distinguish "favorable" from "unfavorable" biology in non-muscle Invasive and more advanced disease that direct us to optimal therapy ("personalized medicine"), the development of novel therapeutic approaches for non-muscle Invasive BC that are alternatives to bacillus Calmette-Guerin (BCG) and/or are effective in BCG-refractory disease, and the Identification of novel agents for the treatment of metastatic BC. To achieve these goals, our SPORE has assembled clinicians and basic scientists including urologists, medical oncologists, pathologists, molecular epidemiologists, molecular and cell biologists, biostatisticians, and experts in development of new technologies and informatics. The SPORE includes 5 inter-related projects that deal with 1) early detection of BC, 2) risk assessment for BC 3) biology and therapeutic targeting of the fibroblast growth factor receptor -3, 4) therapeutic targeting of Ral GTPases, and 5.) the development of adenoviral mediated gene therapy for refractory tumors. These projects are supported by 3 Cores: (A) Administrative; (B). Biostatistics and Bioinformatics; and (C) Pathology & Data Management. All of the scientific projects are translational in nature; focus on human BC; involve clinical and basic investigators and biostatisticians; interact with the other projects; and utilize Core resources. Innovative Developmental and Career Development Projects have brought new investigators into and stimulated the SPORE that are represented in each of the major projects. Achievement of the aims and objectives of this proposal will result in a major decrease in the incidence, morbidity and mortality of BC.